Belite Bio, Inc (BLTE)
| Market Cap | 5.23B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -62.39M |
| Shares Out | 34.89M |
| EPS (ttm) | -1.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 314,480 |
| Open | 151.00 |
| Previous Close | 151.27 |
| Day's Range | 140.07 - 151.79 |
| 52-Week Range | 49.00 - 160.55 |
| Beta | -1.45 |
| Analysts | Strong Buy |
| Price Target | 149.00 (-0.67%) |
| Earnings Date | Nov 10, 2025 |
About BLTE
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding pr... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for BLTE stock is "Strong Buy." The 12-month stock price target is $149.0, which is a decrease of -0.67% from the latest price.
News
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting...
Why Belite Bio Stock Soared on Monday
The biotech's Stargardt disease drug did well in a late-stage clinical trial. This is an eye affliction that can lead to loss of central vision.
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting...
Belite Bio, Inc (BLTE) Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease Transcript
Belite Bio, Inc (BLTE) Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease Transcript
Belite Bio Scores First Successful Phase 3 Trial For Rare Vision-Loss Disease
Belite Bio Inc. (NASDAQ: BLTE) on Monday released topline results from the global Phase 3 DRAGON trial of Tinlarebant, marking the first successful pivotal trial in patients with Stargardt disease typ...
Belite Bio's drug for genetic eye disease meets main goal in late-stage trial
Belite Bio said on Monday that its experimental drug for a rare genetic eye disease met the main goal in a late-stage study.
New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”) today announced topline results from the global Phase 3 “DRAGON” trial of Tinlarebant, marki...
Belite Bio, Inc (BLTE) Q3 2025 Earnings Call Transcript
Belite Bio, Inc ( BLTE) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Julie Fallon Yu-Hsin Lin - Chairman of the Board of Directors & CEO Hao-Yuan Chuang - CFO & Director N...
Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference 2025 Prepared Remarks Transcript
Belite Bio, Inc ( BLTE) Deutsche Bank ADR Virtual Investor Conference 2025 November 4, 2025 10:30 AM EST Company Participants Nathan L. Mata - Chief Scientific Officer Conference Call Participants Za...
Belite Bio to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference November 4th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...
Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting dege...
Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases ...
Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease
SAN DIEGO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting deg...
Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors
SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("Belite Bio" or the "Company") (Nasdaq: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Belite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript
Belite Bio, Inc (NASDAQ:BLTE) Q2 2025 Earnings Conference Call August 11, 2025 4:30 PM ET Company Participants Hao-Yuan Chuang - CFO & Director Hendrik P.N. Scholl - Chief Medical Officer Nathan L.
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases t...
Belite Bio Announces Registered Direct Offering of $15 Million
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degen...
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
- 500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia
Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease
SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative ...
Belite Bio: Investors Face Tricky Decision Ahead Of Key STGD1 Study Readout
Belite Bio's lead drug, Tinlarebant, shows promise in rare eye diseases, but pivotal data and regulatory approval remain at least 18 months away in my view. The DRAGON study's interim analysis is enco...
Belite Bio, Inc (BLTE) Q1 2025 Earnings Call Transcript
Belite Bio, Inc (NASDAQ:BLTE) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Julie Fallon - Investor Relations Tom Lin - Chairman and Chief Executive Officer Nathan Mat...
Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative r...
Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...
Belite Bio to Participate in Four Upcoming Investor Conferences
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative r...
Belite Bio, Inc. (BLTE) Q4 2024 Earnings Call Transcript
Belite Bio, Inc. (NASDAQ:BLTE) Q4 2024 Results Conference Call March 17, 2025 4:30 PM ET Company Participants Julie Fallon - Investor Relations Tom Lin - Chairman and Chief Executive Officer Nathan M...